RAC

2.20%

$1.78 race oncology ltd

Hi @Mason14 I always enjoy your posts and appreciate the...

First 2934 Last

Share
Profile

Follow
easysell

642 Posts.

149

18/06/24

18:03

Post #: 74375463
Share

Originally posted by Mason14: ↑

The reclassification of Bisantrene has been an ongoing topic of discussion. Few people truly understand the drug, but those who do are mostly invested in RAC. Recent discoveries highlighting Bisantrene's world-leading FTO inhibition and cardioprotective mechanisms have allowed RAC and its investors to gain a deeper understanding of the historical clinical and preclinical data.

Many people I speak with still adhere to the outdated view that "Bisantrene is just an old anthracene," a perspective rooted in the knowledge of and drug regimens used by clinicians 40 years ago. There is as much clinical validation supporting Bisantrene's role as an anthracene as there is for FTO inhibition during those early years. For those who have considerable time dissecting historic preclinical and clinical papers recognize the inconsistencies between Bisantrene and other anthracenes, concluding that Bisantrene was functioning clinically as an FTO inhibitor is a straightforward procedure.

The drugs listed below are approved kinase inhibitors with multiple biological targets at different dose ranges. The key takeaway from this table is that pharmaceutical companies and the FDA are well aware of drugs that have multiple biological mechanisms of action.

If Bisantrene was included into this table, it would read:

Bisantrene FTO 0.14uM Cardio X 1.5-2 uM Telomerase 3.6 uM Topoisomerase II 18 uM

My thinking is when pharma are informed about what Bisantrene is and how much history it has, the development stage of clinical and commercial competitors, and how enormous the FTO-inhibitor and CPACS opportunity is, they will be able to connect the dots much like we have. I think it will come down to who wants to be number 1 in the space, and we know how that worked out for Keytruda.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516332/pdf/fonc-12-953013.pdf

Expand

Hi @Mason14 I always enjoy your posts and appreciate the simplicity with which you decipher the information and share with us here.
I seriously think you need to join Dr Peter Smith on a road show to the USA so you can explain this opportunity to the 3 year olds currently working in M&A at BP who are totally missing the forrest for the trees.
Keep up the good work. I owe you a beer at the AGM

RAC Price at posting: $2.01 Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 76 more messages in this thread...

First 2934 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.78		Change -0.040(2.20%)		Mkt cap ! $302.5M

Open	High	Low	Value	Volume
$1.81	$1.82	$1.76	$132.8K	74.40K

Buyers (Bids)

No.	Vol.	Price($)
1	170	$1.77

Sellers (Offers)

Price($)	Vol.	No.
$1.78	2	1

View Market Depth

No.	Vol.	Price($)
1	170	1.765
2	4000	1.755
3	12714	1.750
1	3000	1.740
1	1405	1.720

Price($)	Vol.	No.
1.775	2	1
1.780	3781	1
1.820	2315	1
1.830	7500	1
1.840	1000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

RAC (ASX) Chart

Hi @Mason14 I always enjoy your posts and appreciate the...

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi @Mason14 I always enjoy your posts and appreciate the...

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News